Philadelphia Chromosome - 23 Studies Found
| Active, not recruiting |
: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI :
|
| Completed |
: Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia : Leukemia : 2005-10-25 :
|
| Completed |
: Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias : Chronic Myelogenous Leukemia : 2008-12-17 : Drug: SKI-606 (Bosutinib) Formulation: 100 mg Capsule for |
| Completed |
: Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion : Philadelphia Chromosome-positive Chronic Myelocytic Leukemia : 2009-08-26 : Procedure: Stem cell transplantation Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4 |
| Completed |
: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias : Chronic Myeloid Leukemia : 2005-12-02 : Drug: Bosutinib Part 1, starting dose 400 mg oral, daily d |
| Recruiting |
: A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL :
|
| Completed |
: Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy : Philadelphia Chromosome Positive Chronic Myelogenous Leukemia : 2011-10-14 : Drug: Nilotinib + LDE225 Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosi |
| Completed |
: Rollover Study of BMS-354825 in Patients With CML and Ph+ALL :
|
| Withdrawn |
: Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL :
: 2006-07-06 : Drug: Dasatinib |
| Completed |
: Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia : Philadelphia Chromosome Positive Acute Lymphocytic Leukemia : 2005-09-09 : Drug: Imatinib Mesylate Other Names:
|